Schistosomiasis, caused by infections with Schistosoma japonicum, is one of the human parasitic diseases that remains a public health problem throughout the world's tropical and subtropical regions. With the sustained efforts for six decades, schistosomiasis has been effectively controlled in China. But in the lake region of the schistosomiasis endemic areas, the disease is still a big burden to some specific population, such as fishmen and boatmen, which hinders the local social-economic development. Currently, due to the low infection intensity in population of endemic areas after implementation of the integrated control strategy with multi-interventions [1] , such as health education, preventive chemotherapy with praziquantel, mechanization in agriculture with replacement of water buffalo, and snail elimination through environmental modification, sensitive diagnostics still lack for detecting infections and assessing the effectiveness of the control interventions. Recently, The Lancet Infectious Diseases published the findings from Chinese scientists that a single protein marker dramatically increased the sensitivity and specificity of immunodiagnostic testing of schistosome infection in humans [2] . This study was conducted by a research team led by Prof. Pan WeiQing, consisting of researchers from Tongji University School of Medicine, Jiangxi Provincial Institute of Parasitic Diseases, Medical College of Soochow University, and Second Military Medical University. The investigators carried out a genome-wide identification of diagnostic protein markers for schistosome infection and assessed their diagnostic validity in a field study. They predicted secreted proteins (SjSP) of S. japonicum was achieved through screening at genome-wide scale via bioinformatics technology. Briefly, the screening was performed based on the genome sequences along with the corresponding proteomic and transcriptomic datasets [3, 4] . The putative secreted proteins were cloned and expressed as glutathione S-transferase fusion proteins (GST-SjSPs). The fusion proteins were arrayed on GSH-immobilized microplates and screened with schistosomiasis patient sera. Only one recombinant protein (SjSP-13), out of 204, reacted to the entire panel of 14 archived samples, although the other 35 yielded seropositive reactions, eight showed strong immunoreactivity. The reactivity of SjSP-13 to 476 serum samples showed higher sensitivity (90.4%) and specificity (98.9%), based on laboratory evaluation [2] .
To understand the feasibility of the identified protein marker (SjSP-13) to be used in the national schistosomiasis control program, a field trial was carried out. The field trial was conducted in two villages which located in an endemic area of schistosomiasis in the south-eastern Poyang Lake, Jiangxi Province [2] . Of 1371 enrolled residents, only 74 individuals were identified as being infected by traditional parasitological detection by using Kato-Katz thick smears, while 465 were diagnosed as positive by the SjSP-13-based ELISA kit (rSP13-ELISA). Of the 394 individuals found being egg-negative but rSP13-ELISA-positive, 363 (92.4%) were confirmed to be positive for schistosome infection by PCR detection of S. japonicum SjR2 retrotransposon (Figure 1) . Furthermore, over 70% of the individuals showed seroconversion and all showed a dramatic decline of the anti-SjSP-13 antibody six months after chemotherapy, further demonstrating these individuals had a schistosome infection. Currently, the global schistosomiasis control program has made tremendous progress in terms of reducing the schistosomiasis prevalence and morbidity in many endemic countries, particularly after the London Declaration on Neglected Tropical Diseases. With the goal of the disease elimination, low but persistent levels of schistosomiasis transmission require essential changes in many aspects of elimination approaches [5] . For instance, the new tools of diagnosis and surveillance are urgent to be used in the local settings with low-intensity infections of hosts and in the evaluation of intervention effectiveness. The rSP13-ELISA tool developed by Dr. Xu and his colleagues showed substantial advantages over parasitological detection and SEA-ELISA, including adequate sensitivity and specificity needed in low transmission areas [2] . Application of this tool may allow identification of cases with low-intensity infections and targeted treatment.
The National Schistosomiasis Control Program in China (2004-2015) was issued by Ministry of Health in 2004, with the aim of reducing the prevalence of schistosome infection in all endemic counties down to <5% by the end of 2008, and further down to 1% by the end of 2015 [6] . The success of this program and finally elimination of schistosomiasis in China hinges on the availability of sensitive, simple and affordable diagnostics to be used easily by staff at country level. In the field trial, it has been noticed that only 5% of the enrolled residents were identified as infected with schistosomes by Kato-Katz thick smears, while 33.9% were confirmed by virtue of a positive result from rSP13-ELISA [2] . According to the current control program, all infected individuals with S. japonicum have to be treated in order to eliminate the transmission. While the rSP13-ELISA approach developed in this study was particularly relevant for mild infections. It performed even better than SEA-ELISA as 89.9% of mild infections diagnosed correctly by the rSP13-ELISA kit compared to 79.9% by the SEA-ELISA kit [2] . Therefore, we recommend that further study on cut-off value of the kit is warrant, then it is not so difficult to translate this tool into control program in following three aspects: (i) screening for the treatment of targeted population to achieve the transmission elimination, (ii) screening infected subjects in the surveillance system both in the pre-elimination and post-elimination stages, (iii) providing the certification tool in the elimination of schistosomiasis. Therefore, the research approach to discovery of SjSP-13 protein marker as well as the product of rSP13-ELISA kit could contribute significantly to the elimination of schistosomiasis in China, eventually.
